Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Fiche publication
Date publication
août 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LANG Hervé, Dr LINDNER Véronique, Dr MASSFELDER Thierry
Tous les auteurs :
Lang H, Béraud C, Cabel L, Fontugne J, Lassalle M, Krucker C, Dufour F, Groeneveld CS, Dixon V, Meng X, Kamoun A, Chapeaublanc E, De Reynies A, Gamé X, Rischmann P, Bieche I, Masliah-Planchon J, Beaurepere R, Allory Y, Lindner V, Misseri Y, Radvanyi F, Lluel P, Bernard-Pierrot I, Massfelder T
Lien Pubmed
Résumé
Muscle-invasive bladder cancer (MIBC) and upper urinary tract urothelial carcinoma (UTUC) are molecularly heterogeneous. Despite chemotherapies, immunotherapies, or anti-fibroblast growth factor receptor (FGFR) treatments, these tumors are still of a poor outcome. Our objective was to develop a bank of patient-derived xenografts (PDXs) recapitulating the molecular heterogeneity of MIBC and UTUC, to facilitate the preclinical identification of therapies.
Mots clés
basal tumors, luminal tumors, molecular subtypes, squamous cell carcinoma, tumor heterogeneity, tyrosine kinase receptor, upper-urinary tract carcinoma, urothelial carcinoma
Référence
Front Oncol. 2022 08 11;12:930731